Improving treatment for rectal cancer by targeting tryptophan metabolism
Targeting Tryptophan Metabolism in Rectal Cancer
['FUNDING_R01'] · WASHINGTON UNIVERSITY · NIH-10932926
This study is looking at how a specific part of your body's metabolism affects the growth of locally advanced rectal cancer and how well treatments work, with the goal of finding better ways to help patients respond to their treatments.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-10932926 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing treatment outcomes for locally advanced rectal cancer (LARC) by investigating the role of tryptophan metabolism in tumor growth and treatment resistance. The study utilizes patient samples and pre-clinical models to explore the effects of combining short course radiation therapy with an IDO1 inhibitor, which is known to suppress immune responses in tumors. By understanding how IDO1 overexpression contributes to treatment resistance, the research aims to develop more effective therapeutic strategies that could improve patient responses to existing treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with locally advanced rectal cancer who are undergoing or considering neoadjuvant therapy.
Not a fit: Patients with early-stage rectal cancer or those who have already received extensive treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and better survival rates for patients with locally advanced rectal cancer.
How similar studies have performed: Previous research has shown promising results in targeting metabolic pathways in cancer treatment, suggesting that this approach may yield significant advancements.
Where this research is happening
SAINT LOUIS, UNITED STATES
- WASHINGTON UNIVERSITY — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CIORBA, MATTHEW AARON — WASHINGTON UNIVERSITY
- Study coordinator: CIORBA, MATTHEW AARON
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Center